Tesofensine

Tesofensine is a triple monoamine reuptake inhibitor (SNDRI), blocking the serotonin, noradrenaline and dopamine transporters. It is a phenyltropane small molecule, not a peptide and not an incretin analogue, and works on central monoamine systems rather than gut hormone receptors.

Developed by NeuroSearch as NS2330 for Alzheimer's and Parkinson's disease, it showed limited efficacy in those indications but a consistent weight signal. In a meta-analysis of four randomised, double-blind trials in Parkinson's and Alzheimer's patients, obese patients on 1.0 mg lost 3.7% of body weight in 14 weeks with no diet or lifestyle intervention, and 32.1% achieved at least 5% weight loss versus 2.1% on placebo. Rights transferred to Saniona in 2014; the Phase 2 obesity trial TIPO-1 appeared in The Lancet in 2008, and a Phase 3 trial was completed in Mexico by Medix in 2018. COFEPRIS issued a favourable opinion in 2023. As of early 2026 there is no final market approval anywhere and no FDA approval.

Pharmacokinetics: oral bioavailability greater than 90%, Tmax 5 to 8 hours, food-independent absorption, terminal half-life approximately 234 hours (about 10 days), steady state at roughly 6 to 8 weeks. Primary metabolism is via CYP3A4 to the active desalkyl metabolite M1, half-life approximately 374 hours, with steady-state exposure around 31 to 34% of parent. CYP3A4 inhibitors and inducers therefore materially shift exposure.

The dominant prescribing constraint is serotonergic. Concurrent SSRIs, SNRIs, MAOIs, bupropion, triptans, serotonergic opioids and other serotonergic agents carry serotonin syndrome risk, and the earlier exclusion list for this compound runs to roughly fifty named agents spanning SSRIs, SNRIs, tricyclics, MAOIs, triptans, serotonergic opioids, antiemetics, anticonvulsants, antipsychotics and St John's Wort.

The combined clinical safety database includes approximately 1,600 patients treated with therapeutic doses across more than 20 clinical trials.

Tesofensine blocks the serotonin, noradrenaline and dopamine transporters, prolonging synaptic residence of all three monoamines. Serotonin contributes satiety signalling, noradrenaline drives energy expenditure, arousal and sympathetic activation with appetite suppression via downstream alpha-1 adrenergic activation, and dopamine modulates food reward and motivation. Obesity is associated with reduced dopaminergic signalling, and increased synaptic dopamine is proposed to correct that deficit.

It is the first compound to block all three transporters meaningfully at weight loss doses. Sibutramine, withdrawn in 2010 for cardiovascular risk, was serotonergic and noradrenergic without meaningful dopaminergic action; bupropion is noradrenergic and dopaminergic without meaningful serotonergic action.

PET imaging with [11C]betaCIT-FE at anticipated steady state showed mean striatal dopamine transporter occupancy of 18% to 77% across 0.125 to 1.0 mg, with maximum achievable occupancy estimated at approximately 80% and half-maximal effect at about 0.25 mg and a plasma concentration of 4 ng/ml.

The hypothalamic mechanism was defined in 2024 work using ensemble electrophysiology, optogenetics and chemogenetics: tesofensine inhibits a subset of GABAergic neurons in the lateral hypothalamus that promote feeding, and chemogenetic silencing of those neurons enhanced the anorectic effect. Weight loss was greater in obese than lean animals, and appetite suppression was independent of taste aversion.

Receptor-level work in diet-induced obese rats places the anorectic signal on indirect alpha-1 adrenoceptor and dopamine D1 pathways: prazosin almost completely reversed the effect, SCH23390 partially reversed it, and alpha-2, D2/D3 and 5-HT2A/C antagonists showed no involvement. ED50 was 1.3 mg/kg.

Energy expenditure is a genuine second arm. In a respiration chamber study of 32 overweight and moderately obese men, 24-hour fat oxidation rose by 18 grams versus placebo, nighttime energy expenditure rose 4.6% adjusted for body composition, and 1.8 kg more weight loss than placebo occurred in two weeks despite controlled feeding. In rats, pair-fed controls regained weight by day 28 while tesofensine-treated animals maintained 9.9% loss.

Metabolism is via CYP3A4 to the active metabolite M1.

Weight and appetite: appetite suppression, reduced cravings, promotion of satiety, reduced adipose tissue with abdominal fat specifically targeted, increased resting energy expenditure, increased fat oxidation and boosted metabolism. In TIPO-1, 0.5 mg gave 11.2% mean weight loss at 24 weeks (9.2% placebo-subtracted) versus 2.0% on placebo, with dose-dependent reductions in body fat and waist circumference, improved plasma lipids and improved quality of life. Phase 3 confirmed roughly 10% mean loss with more than half of patients on the therapeutic dose exceeding 10%. Strongly indicated for binge eating disorder.

Metabolic: Phase 3 showed reduced waist and hip circumference, body fat, visceral fat, VLDL cholesterol, triglycerides and insulin. Animal work showed improved glycaemic control on oral glucose tolerance testing beyond caloric restriction alone, and suppression of the plasma insulin response. Improved insulin sensitivity and glucose metabolism, reduced blood glucose, increased energy.

Cognitive: preservation of cognitive health via indirect increase in cholinergic neurotransmission, with claimed benefit across CNS regions for learning, memory and thinking, and possible utility in Alzheimer's and Parkinson's.

Mood and affect: increased BDNF producing an antidepressant effect; anxiolytic action in comorbid depression and anxiety; increased serotonin, noradrenaline and dopamine. Note the opposing signal at higher doses — depressed mood in 6.1% at 1.0 mg versus 0% placebo.

ADHD: symptom improvement, tied to the dopamine and serotonin deficits characteristic of the condition.

Sleep: treats serotonin-deficient insomnia, but insomnia is also a dose-dependent adverse effect, so direction is phenotype- and timing-dependent.

Sexual function: increased desire, improved erectile and ejaculatory function, attributed to the dopaminergic arm.

Addiction: dopaminergic elevation proposed as a route to treating alcohol dependence. Abuse potential itself is low — in 52 recreational stimulant users, subjective effects were not significantly different from placebo, significantly lower than D-amphetamine, and no greater than bupropion or atomoxetine, attributed to the 5 to 8 hour Tmax.

Route advantage: once-daily oral capsule with stable steady-state levels and no peak-trough swings.

Onset is slow by design. With a half-life around 234 hours, accumulation towards steady state takes roughly 6 to 8 weeks, and full effect is not available before then. Over the first 1 to 2 weeks most report a gradual reduction in appetite and craving intensity, some mild alertness or activation consistent with noradrenergic and dopaminergic reuptake blockade, and dry mouth within the first few days.

Through weeks 2 to 8 the anorectic effect sharpens. The characteristic report is loss of food noise rather than gastric fullness: the drive to seek food falls while digestion remains normal. Weight loss becomes measurable at roughly 1 to 2 pounds per week depending on dose and dietary control. In practice, users at 250 to 500 mcg daily report 8 to 15 pounds over the first 4 to 8 weeks, described as steady and progressive rather than rapid, and generally smaller in magnitude than GLP-1 agonist results.

From weeks 8 to 24 the trial data show progressive loss: the TIPO-1 0.5 mg group lost a mean of 11.3 kg (about 25 pounds) over 24 weeks with weight still declining at trial end.

The qualitative contrast with incretin therapy is consistent. GLP-1 agonists generate physical fullness through delayed gastric emptying; tesofensine leaves gastric emptying untouched and acts on central reward and appetite circuitry. Consequently the nausea and vomiting typical of incretin titration are absent, replaced by dry mouth and constipation, the latter generally milder than on GLP-1 agonists.

Activation-related effects are the main tolerability variable. Increased alertness, focus and mild mood elevation are common early; a minority report anxiety, restlessness or feeling wired, more often at higher doses or in stimulant-sensitive individuals. Sleep disruption is the most discussed concern and is largely resolved by morning-only dosing, though lighter sleep or early waking can persist in the first few weeks. Insomnia was reported in approximately 50% of patients in the Tesomet hypothalamic obesity trial, mostly mild to moderate. Users tracking resting heart rate typically report a 5 to 10 bpm rise, consistent with trial data.

Oral capsule, once daily in the morning. Vendor capsules are typically 250 mcg or 500 mcg. Titration: 0.25 mg (250 mcg) once daily in the morning for weeks 1 to 2, then 0.5 mg (500 mcg) once daily in the morning from week 3 onward. Morning administration limits sleep disruption. Food does not affect bioavailability, so timing relative to meals is free.

Pharmacokinetic context: half-life approximately 234 hours (10 days), steady state at 4 to 5 half-lives, roughly 6 to 8 weeks. Full effect is not available before steady state, so early dose escalation on the basis of perceived underresponse is premature. Do not exceed 0.5 mg daily without medical supervision.

Dose selection rests on the 24-week data: 0.25 mg gave 6.5% weight loss with the best tolerability, 0.5 mg gave 11.2% with good tolerability, and 1.0 mg gave 12.6% with significantly more adverse events. The 0.25 to 0.5 mg step nearly doubles efficacy; the 0.5 to 1.0 mg step adds about 1.4 percentage points at the cost of increased heart rate, psychiatric adverse events (6.1% depressed mood versus 0% placebo, including one case of major depression) and higher discontinuation. Hence 0.5 mg as the therapeutic dose and 1.0 mg as generally not recommended.

A 250 mcg maintenance dose is defensible for stimulant-sensitive individuals, those on potentially interacting medications, or a conservative approach: PET data show approximately half of maximum dopamine transporter occupancy at 0.25 mg.

Duration: both the Phase 2 and Phase 3 trials ran 24 weeks, with weight still declining at trial end. No published long-term data exist beyond 24 weeks in obese populations, and behaviour over 12 months or more of continuous use is unknown.

Monitoring is cardiovascular and psychiatric rather than glycaemic: resting heart rate, blood pressure through the first month, mood, sleep, and daily protein intake, since appetite suppression can drive severe undereating. CYP3A4 inhibitors and inducers shift exposure. The medication review is the real gate — the serotonergic exclusion list rules out a substantial share of users on antidepressants, triptans or serotonergic analgesics.

The evidence base spans Phase 2, Phase 3, mechanistic human imaging, a dedicated metabolic study, an abuse liability study, and rodent work. Combined safety database: approximately 1,600 patients on therapeutic doses across more than 20 trials.

TIPO-1 (Astrup et al., 2008), The Lancet. 203 obese patients (BMI 30 to 40), five Danish obesity centres, randomised to 0.25, 0.5, or 1.0 mg or placebo for 24 weeks with energy-restricted diet; 79% completion. Weight loss 6.5%, 11.2%, 12.6% versus 2.0% placebo (placebo-subtracted 4.5%, 9.2%, 10.6%); absolute 6.7, 11.3, 12.8 versus 2.2 kg. Dose-dependent reductions in body fat and waist circumference, improved plasma lipids, improved quality of life. At 0.5 mg: heart rate +7.4 bpm (p = 0.0001), no significant systolic change, 8% adverse-event discontinuation.

Neurological disease meta-analysis (Astrup et al., 2008), Obesity. Four randomised double-blind trials (two Parkinson's, two Alzheimer's), 740 on tesofensine versus 228 placebo, 14 weeks, no lifestyle intervention. Weight change: placebo +0.5%, 0.125 mg -0.5%, 0.25 mg -0.9%, 0.5 mg -1.8%, 1.0 mg -2.8% (p = 0.015). Obese subgroup at 1.0 mg lost 3.7%; 32.1% achieved at least 5% loss.

Phase 3 (Medix/Saniona, 2018). 372 adults randomised 1:1:1 to 0.25 mg, 0.5 mg, or placebo for 24 weeks. Primary and secondary endpoints met (p < 0.001, ITT-LOCF and completers), ~10% mean weight loss, more than half of therapeutic-dose patients above 10%, with reductions in BMI, waist and hip circumference, body fat, visceral fat, VLDL cholesterol, triglycerides, and insulin.

TIPO-2 (Sjodin et al., 2010): 32 men, respiration chamber, 2.0 mg for 7 days then 1.0 mg for 7 days. 24-hour fat oxidation +18 g (p < 0.001), night-time energy expenditure +4.6% adjusted (p < 0.05), 1.8 kg greater weight loss than placebo in 2 weeks (p < 0.0001), higher satiety and fullness ratings.

Appel et al., 2014 PET with [11C]betaCIT-FE: striatal DAT occupancy 18% to 77% across 0.125 to 1.0 mg, maximum ~80%, half-maximal at ~0.25 mg and 4 ng/ml plasma. Axel et al., 2010: appetite suppression reversed almost completely by prazosin (alpha-1) and partially by SCH23390 (D1); ED50 1.3 mg/kg; no involvement of alpha-2, D2/D3, or 5-HT2A/C. Hansen et al., 2010: 9.9% sustained weight loss over 28 days versus 7.6% sibutramine, with pair-fed controls regaining. Perez et al., 2024 (PLOS ONE): silencing of feeding-promoting GABAergic lateral hypothalamic neurons, greater effect in obese than lean animals, appetite suppression independent of taste aversion. Schoedel et al., 2010: no abuse signal above placebo in 52 recreational stimulant users. Huynh et al., 2022: Tesomet produced 6.6% weight loss beyond placebo in hypothalamic obesity, 61.5% versus 12.5% achieving at least 5%.